ArticleGynecologic oncology reports2025
Oligometastatic granulosa cell tumor treated with stereotactic body radiation therapy with a radiographic and tumor marker response.
Article in Gynecologic oncology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Stereotactic body radiation therapy (SBRT) is a safe and effective treatment for oligometastatic gynecologic cancers. This report details the case of a 75-year-old woman with recurrent granulosa cell tumor of the left ovary. The patient was diagnosed with a peritoneal recurrence after her inhibin-B level increased to 39.7 pg/mL, and a subsequent computed tomography (CT) scan of the abdomen and pelvis revealed an enlarging left-sided soft tissue mass in the sigmoid mesentery measuring 1.2 × 1.2 cm. She underwent SBRT, delivering 37.5 Gy in 5 fractions to the soft tissue mass. A CT scan post-treatment indicated the mass had decreased to 0.8 cm and that her inhibin B level decreased to < 7 pg/mL. This case highlights the effectiveness of SBRT in the management of oligometastatic ovarian cancer, achieving a marked radiographic and tumor marker response in patients with disease not amenable to surgical resection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.